Life Science Integrates
Formed in 2011 by Christopher Watt and Samuel Thangiah, Life Science Integrates (LSI) brings together Senior Leaders from across the Life Sciences, including industry, academia, government and regulators; providing them with unique opportunities to be part of the conversations that set out the industry’s challenges and identify effective strategies and solutions.
Our purpose is to find novel and engaging ways to bring people together; to discuss, debate and uncover the strategic solutions to their industry’s challenges by creating environments that challenge traditional concepts and enable constructive debate around disruptive innovations, business models and supply chains to ensure that today’s ideas and concepts will become the effective therapies and diagnostics of the future. Ultimately helping to ensure that the Life Science Industry delivers the best possible outcomes for patients and carers.
Life Science Integrates has enabled the conversations that have helped shape our industry today and will set the direction for the future.
Non Executive Director
Events & Marketing Manager
LIVE ONLINE 15 October 2020
Addressing the needs of the MedTech community to overcome the challenges needed to achieve a transformation of diagnostics and devices in healthcare.
LIVE ONLINE 16 November 2020
Focused on the biotech, start-up and emerging pharma sector addressing the needs of innovative companies that develop therapies of tomorrow.
LIVE ONLINE 17 November 2020
Bringing together pharma and healthcare leaders across the Pharmaceutical pipeline to address their needs, to share insights and create debate on crucial topics that influence the future of patient outcomes.
Life science insights
Nanoform Finland Plc, an innovative nanoparticle medicine enabling company, and Aprecia, the 3DP (three-dimensional printing) pharmaceutical company, announce that they are exploring the synergies between their respective technologies in the field of nanoparticle-enabled 3DP dosage forms.
Nanoform launches next-generation STARMAP® v2.0, the AI-based drug candidate selection tool for CESS®
Nanoform Finland Plc, an innovative nanoparticle medicine enabling company, has today launched the next generation of its STARMAP® AI (artificial intelligence) platform, v2.0.
The epicentre of the drug industry: how CROs’ breadth, talent, diversity and expertise supported unprecedented sector growth to become the backbone of biopharma
In recent years Contract Research Organisations (CROs) have become the backbone of pharma and biotech research and development (R&D), the go-to source for in-depth know-how and niche expertise no longer available within such organisations.
Sign up for life science integrates news
Get the latest news and updates by signing up today.